- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib
-
- Vaia Florou
- 1Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah; and
-
- Christopher Nevala-Plagemann
- 1Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah; and
-
- Jonathan Whisenant
- 1Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah; and
-
- Patricia Maeda
- 2Bayer Healthcare Pharmaceuticals, Whippany, New Jersey
-
- Glynn W. Gilcrease
- 1Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah; and
-
- Ignacio Garrido-Laguna
- 1Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah; and
Search this article
Description
<jats:p><jats:italic>NTRK </jats:italic>gene fusions are found in <1% of all cancers but are uniformly present in mammary analog secretory carcinomas (MASC) of the salivary glands. Two selective histology-agnostic tropomyosin receptor kinase (TRK) inhibitors are currently approved for malignancies with these oncogenic fusions. Resistance to TRK inhibition has been recognized, and the mediating mechanisms are presently being studied. This report describes a patient diagnosed with an MASC of the parotid gland who after undergoing multiple lines of treatment was found to have an <jats:italic>ETV6-NTRK3</jats:italic> fusion and initiated TRK-targeted therapy using entrectinib. Upon disease progression, we performed tumor genetic sequencing that showed a secondary resistance mutation. The patient subsequently responded to selitrectinib, a next-generation TRK inhibitor.</jats:p>
Journal
-
- Journal of the National Comprehensive Cancer Network
-
Journal of the National Comprehensive Cancer Network 19 (5), 478-482, 2021-05
Harborside Press, LLC
- Tweet
Details 詳細情報について
-
- CRID
- 1360298345429032320
-
- ISSN
- 15401413
- 15401405
-
- Data Source
-
- Crossref